Connor, Clark & Lunn Investment Management (CC&L)’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-9,309
| Closed | -$264K | – | 1547 |
|
|
2023
Q1 | $264K | Buy |
+9,309
| New | +$264K | ﹤0.01% | 1035 |
|
|
2020
Q3 | – | Sell |
-5,251
| Closed | -$252K | – | 1159 |
|
|
2020
Q2 | $252K | Buy |
+5,251
| New | +$252K | ﹤0.01% | 867 |
|
|
2020
Q1 | – | Sell |
-6,250
| Closed | -$376K | – | 1200 |
|
|
2019
Q4 | $376K | Sell |
6,250
-24,483
| -80% | -$1.47M | ﹤0.01% | 723 |
|
|
2019
Q3 | $1.74M | Sell |
30,733
-8,185
| -21% | -$463K | 0.01% | 435 |
|
|
2019
Q2 | $2.17M | Buy |
38,918
+150
| +0.4% | +$8.35K | 0.01% | 420 |
|
|
2019
Q1 | $1.96M | Buy |
38,768
+1,575
| +4% | +$79.5K | 0.01% | 414 |
|
|
2018
Q4 | $1.5M | Sell |
37,193
-3,100
| -8% | -$125K | 0.01% | 468 |
|
|
2018
Q3 | $2.79M | Buy |
40,293
+300
| +0.8% | +$20.8K | 0.02% | 391 |
|
|
2018
Q2 | $3.03M | Sell |
39,993
-6,432
| -14% | -$487K | 0.02% | 395 |
|
|
2018
Q1 | $2.45M | Buy |
46,425
+11,400
| +33% | +$601K | 0.01% | 365 |
|
|
2017
Q4 | $1.87M | Buy |
35,025
+12,725
| +57% | +$680K | 0.01% | 426 |
|
|
2017
Q3 | $1.33M | Buy |
+22,300
| New | +$1.33M | 0.01% | 488 |
|